<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03737188</url>
  </required_header>
  <id_info>
    <org_study_id>IDT-1722-IU</org_study_id>
    <nct_id>NCT03737188</nct_id>
  </id_info>
  <brief_title>Institut Fuer Diabetes-Technologie Surveillance Program</brief_title>
  <official_title>Institut Fuer Diabetes-Technologie Surveillance Program for Blood Glucose Monitoring Systems in Europe</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Institut für Diabetes-Technologie Forschungs- und Entwicklungsgesellschaft mbH an der Universität Ulm</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Institut für Diabetes-Technologie Forschungs- und Entwicklungsgesellschaft mbH an der Universität Ulm</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Assessment of the system accuracy of different blood glucose monitoring systems available in&#xD;
      Europe&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      A variety of blood glucose monitoring systems (BGMS) are available on the European market.&#xD;
      For many of these BGMS, the system accuracy is unknown or it has not yet been assessed in&#xD;
      manufacturer-independent studies. The IDT surveillance program aims at assessing the system&#xD;
      accuracy of different BGMS that are available in Europe in a manufacturer-independent,&#xD;
      investigator-initiated study. The initial study will cover 18 BGMS from 18 different&#xD;
      manufacturers. Per BGMS, one test strip lot will be assessed based on procedures stated in&#xD;
      the international standard ISO 15197:2013 / EN ISO 15197:2015.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">November 14, 2018</start_date>
  <completion_date type="Actual">December 5, 2018</completion_date>
  <primary_completion_date type="Actual">December 5, 2018</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Analysis of system accuracy based on ISO 15197</measure>
    <time_frame>For each subject, the experimental phase has an expected duration of up to 6 hours</time_frame>
    <description>Assessment of the analytical measurement performance of 18 blood glucose montoring systems based on procedures defined in ISO 15197</description>
  </primary_outcome>
  <enrollment type="Actual">126</enrollment>
  <condition>Diabetes</condition>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Blood glucose monitoring systems for self-testing</intervention_name>
    <description>Capillary blood samples will be used for the evaluation of system accuracy.</description>
    <other_name>18 BGMS from 18 different manufacturers: ABRA, Accu-Chek Guide, AURUM Blutzucker-Messsystem, CareSens Dual, CERA-CHEK 1 Code, Contour next ONE, eBsensor, FreeStyle Freedom Lite, GL 50 (evo)</other_name>
    <other_name>GlucoCheck GOLD, GlucoMen areo 2K, GluNEO, MyStar DoseCoach, OneTouch Verio Flex, Pic GlucoTest, Rightest GM700S, TRUEyou Blutzuckermesssystem, WaveSense JAZZ WIRELESS</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Male or female, with type 1 diabetes, type 2 diabetes or subjects without diabetes&#xD;
&#xD;
          -  Signed informed consent form&#xD;
&#xD;
          -  Minimum age of 18 years&#xD;
&#xD;
          -  ubjects are legally competent and capable to understand character, meaning and&#xD;
             consequences of the study.&#xD;
&#xD;
          -  If blood glucose values &lt; 80 mg/dl or &gt; 300 mg/dl shall be measured after short term&#xD;
             alteration in insulin therapy:&#xD;
&#xD;
          -  Male or female with type 1 diabetes and intensified insulin therapy or insulin pump&#xD;
             therapy.&#xD;
&#xD;
          -  Signature of subjects to document consent with these procedures on informed consent&#xD;
             form.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Pregnancy or lactation period&#xD;
&#xD;
          -  Severe acute disease (at the study physician's discretion)&#xD;
&#xD;
          -  Severe chronic disease with potential risk during the test procedures (at the study&#xD;
             physician's discretion)&#xD;
&#xD;
          -  Current constitution that compromises the subject's capability to participate in the&#xD;
             study (at the study physician's discretion)&#xD;
&#xD;
          -  Being unable to give informed consent&#xD;
&#xD;
          -  &lt; 18 years&#xD;
&#xD;
          -  Legally incompetent&#xD;
&#xD;
          -  Being committed to an institution (e.g. psychiatric clinic)&#xD;
&#xD;
          -  Language barriers potentially compromising an adequate compliance with study&#xD;
             procedures&#xD;
&#xD;
          -  Dependent on investigator or sponsor&#xD;
&#xD;
          -  If blood glucose values &lt; 80 mg/dl shall be measured after short term alteration in&#xD;
             insulin therapy, subjects with type 1 diabetes, suffering from:&#xD;
&#xD;
          -  Coronary heart disease&#xD;
&#xD;
          -  Condition after myocardial infarction&#xD;
&#xD;
          -  Condition after cerebral events&#xD;
&#xD;
          -  Peripheral arterial occlusive disease&#xD;
&#xD;
          -  Hypoglycemia unawareness&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Institut für Diabetes-Technologie Forschungs- und Entwicklungsgesellschaft an der Universität Ulm</name>
      <address>
        <city>Ulm</city>
        <zip>89081</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>February 2019</verification_date>
  <study_first_submitted>October 5, 2018</study_first_submitted>
  <study_first_submitted_qc>November 7, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">November 9, 2018</study_first_posted>
  <last_update_submitted>February 25, 2019</last_update_submitted>
  <last_update_submitted_qc>February 25, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">February 26, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

